Scancell Holdings (SCLP) RNS Announcements

Add to Alert list
Date Time Source Announcement
20 Oct 2015 07:00 AM
RNS
AGM Business Update
14 Oct 2015 07:00 AM
RNS
Directorate Change
06 Oct 2015 07:00 AM
RNS
Six scientific presentations at PIVAC Conference
18 Sep 2015 07:00 AM
RNS
Final Results for the year ended 30 April 2015
16 Sep 2015 07:00 AM
RNS
ImmunoBody presented at Cancer Vaccines Conference
27 Aug 2015 04:42 PM
RNS
Notice of AGM
30 Jul 2015 07:00 AM
RNS
Collaboration with ImmunID
09 Jul 2015 07:00 AM
RNS
Patient recruitment completed for SCIB1 trial
02 Jun 2015 07:00 AM
RNS
SCIB1 data update in resected melanoma patients
18 May 2015 07:00 AM
RNS
Update on SCIB1 data at 2015 ASCO Annual Meeting
17 Apr 2015 09:00 AM
RNS
Poster on Moditope to be presented at AACR
24 Mar 2015 04:40 PM
RNS
Second Price Monitoring Extn
24 Mar 2015 04:35 PM
RNS
Price Monitoring Extension
24 Mar 2015 07:00 AM
RNS
SCIB2 synergy with checkpoint inhibitor blockade
12 Jan 2015 07:00 AM
RNS
Positive SCIB1 Phase 1/2 clinical trial update
15 Dec 2014 05:22 PM
RNS
Holding(s) in Company
10 Dec 2014 07:00 AM
RNS
Half Yearly Report
22 Oct 2014 03:07 PM
RNS
Change of Registered Office
14 Oct 2014 06:19 PM
RNS
Result of AGM
14 Oct 2014 07:00 AM
RNS
Appointment of Nominated Adviser and Broker
14 Oct 2014 07:00 AM
RNS
AGM research and development update
30 Sep 2014 07:00 AM
RNS
Present at the 14th Annual Biotech in Europe Forum
19 Sep 2014 09:57 AM
RNS
Notice of AGM
12 Sep 2014 07:00 AM
RNS
Presenting at Upcoming Scientific Conferences
04 Sep 2014 07:00 AM
RNS
Final Results
12 Aug 2014 07:00 AM
RNS
Synergy of SCIB1 with checkpoint inhibitors
19 Jun 2014 07:00 AM
RNS
Director/PDMR Shareholding
06 Jun 2014 07:00 AM
RNS
DNA ImmunoBody Patent Granted in United States
02 Jun 2014 07:00 AM
RNS
Update on Phase 1/2 trial of SCIB1 in melanoma
15 May 2014 07:30 AM
RNS
Presents latest SCIB1 data at ASCO
09 May 2014 08:30 AM
RNS
Directorate Change
01 May 2014 07:00 AM
RNS
Dr Sally Adams to Join as Development Director
04 Apr 2014 07:00 AM
RNS
Scancell to present SCIB1 at AACR
21 Mar 2014 07:00 AM
RNS
8mg Higher Dose SCIB1 Study On Track
18 Feb 2014 07:00 AM
RNS
Publication of Moditope Patent
11 Feb 2014 07:00 AM
RNS
SCIB1 Granted FDA Orphan Drug Status
10 Feb 2014 04:43 PM
RNS
Holding(s) in Company
06 Jan 2014 07:00 AM
RNS
Nottingham Technology Grant
16 Dec 2013 07:00 AM
RNS
Nottingham Trent University Cancer Protein Study
12 Dec 2013 07:00 AM
RNS
DNA ImmunoBody Patent Granted in Japan
11 Dec 2013 07:00 AM
RNS
Director/PDMR Shareholding
09 Dec 2013 07:00 AM
RNS
New data for SCIB1 in metastatic melanoma
09 Dec 2013 07:00 AM
RNS
Half Yearly Report
18 Nov 2013 07:00 AM
RNS
Re Agreement with Ichor
01 Nov 2013 04:56 PM
RNS
AGM Statement
22 Oct 2013 08:00 AM
RNS
Director/PDMR Shareholding
14 Oct 2013 10:10 AM
RNS
Holding(s) in Company
08 Oct 2013 02:54 PM
RNS
Notice of AGM
01 Oct 2013 07:00 AM
RNS
Investor Update
24 Sep 2013 07:00 AM
RNS
Investor Update Agenda

Scancell Holdings PLC is a biopharmaceutical company that develops vaccines and other therapies to treat cancer and infectious diseases. Scancell's research focuses on the human immune system and how to use it to develop new treatments. Scancell uses four technology platforms to develop its products: ImmunoBody, Moditope, GlyMab and AvidiMab.

Scancell was founded in 1997 based on research led by Professor Lindy Durrant at the University of Nottingham.

Scancell Holdings PLC is listed on the London Stock Exchange (LSE) as SCLP.

Scancell share price listed at 8p in 2010.

UK 100

Latest directors dealings